32experience

31 Years Of Experience

History

USAOTP

In the spring of 1993, a dedicated group of methadone treatment providers gathered in Austin, Texas, united by their shared concern over the lack of representation in matters affecting their regulation and growth. Recognizing the need for a unified voice, Oscar Jones of Lubbock, Texas—a visionary in the field—proposed the formation of a statewide association, inspired by the Northeastern Methadone Association. This pivotal meeting resulted in the creation of the Texas Methadone Treatment Association, with Steven Tapscott serving as the first president and Oscar Jones as vice president. Among the founding members were Dr. Alex John, Jr., Moses Esquivel, Dr. James Sabal, and Farrukh Shamsi.

As the association grew, it began hosting semi-annual meetings, primarily in Austin and occasionally in San Antonio. During one of these meetings in San Antonio in the early 2000s, the future of opioid treatment came into focus: the need to embrace medications beyond methadone. With opioid dependence at the heart of the association’s mission, the presence of providers from outside Texas prompted discussions about the organization’s identity. The use of “Texas” in the name was seen as too restrictive, and Farrukh Shamsi proposed a new name— The United States Association of Opioid Treatment Providers (USAOTP). This marked a significant moment. Following the meeting, the tradition of annual gatherings in Austin, Texas, was established, with exhibitors presenting services and solutions tailored to support the needs of providers.

Austin was not only chosen for its central location but also for its proximity to regulatory bodies based in the city. This facilitated strong relationships with key agencies like SAMHSA and CSAT, with USAOTP representatives actively participating in national discussions, including the development of new accreditation guidelines in Washington, D.C.

Today, USAOTP is closely aligned with the majority of opioid treatment providers in Texas and remains at the forefront of innovation in the field. The introduction of injectable naltrexone, which also treats alcohol dependence on a monthly basis, and injectable buprenorphine, with flexible treatment schedules ranging from weekly to every few months, represent the organization’s commitment to evolving treatment options. USAOTP continues to lead by ensuring its members stay informed about emerging therapies and new treatment settings while expanding services beyond opioid dependence.